*PCR-based molecular assay captured the largest share in the overall market in 2016 due to extensive adoption in HLA typing
*The sequencing-based typing segment is anticipated to witness significant growth from 2016 to 2024.
For More Information on This Report, Please Visit @ https://www.mrrse.com/asia-preimplantation-genetic-diagnosis-market The information presented in this review is based on a MRRSE report, titled "Preimplantation Genetic Diagnosis Market (Test - PGD for Chromosomal Aberrations, Aneuploidy Screening, Gender Selection, Single Gene Disorder, HLA Typing
, and X-linked Diseases) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020." The global PGD market has been segmented as presented below: Global PGD Market by Test
Pacific Biosciences announced that a retrospective study conducted by scientists at the Anthony Nolan Research Institute in the UK demonstrated that ultra-high-resolution HLA typing
performed with PacBio sequencing identified stronger matches associated with improved survival rates among patients who received hematopoietic cell transplants.
Preimplantation Genetic Testing to find Largest Application in Embryo HLA Typing
for Stem Cell Therapy Embryo HLA typing
for stem cell therapy is expected to show healthy growth from throughout 2017-2022.
Advances in DNA sequencing have revolutionized many tests commonly used in or ordered by clinical laboratories, but the implications for HLA typing
have been particularly impressive.
From the HLA Typing
Research Unit (Zalzala, Mohammedsalih, Mahdi), College of Medicine, and from the Department of Medicine (Abdullah, Yaseen), Al-kindy College of Medicine, University of Baghdad, Baghdad, Iraq.
by serology: During the last 40 years HLA typing
to detect this polymorphism was undertaken by the serological method better known as the complement-dependent cytotoxicity assay (CDC).
In this optic, HLA typing
emerges as an important tool able to discriminate individuals genetically susceptible to CD in at-risk groups such as those with autoimmune conditions (e.g., thyroiditis) (4).
Because of the lower throughput of the available technologies and to reduce the number of polymorphic sites to interrogate, early molecular strategies for clinical HLA typing
focused on characterization of the antigen recognition site only (exons 2 and 3 for class I; exon 2 for class II).
Based on test type, the market is segmented into antibody screening, HLA typing
, cross-matching tests, ABO blood tests, and antigen typing.
The comapny, through its recently acquired Olerup franchise, has a presence in the pre-transplant HLA typing